EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Impact of Warfarin and Dual Antiplatelet Therapy on Graft Failure After Coronary Endarterectomy: A Retrospective Cohort Study

Jianfan Zhen iD, Xiang Luo, Jie Liu, Zerui Chen, Jinlin Wu, Tucheng Sun

Cardiovascular Drugs and Therapy · 2026-02 · 40 (1) · 181-189

DOI: 10.1007/s10557-024-07667-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 14.01.2025. Verfasst von Jianfan Zhen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, The Department of Cardiovascular Surgery, Guangdong Cardiovascular Ins…. Hauptthemen laut MEDLINE: Warfarin, Platelet Aggregation Inhibitors, Coronary Artery Bypass, Coronary Artery Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Coronary endarterectomy combined with coronary artery bypass grafting (CE-CABG) effectively achieves coronary revascularization in patients with diffuse atherosclerotic coronary artery disease (CAD). However, the loss of the subendothelial tissue at the CE-CABG coronary artery accelerates local thrombosis, leading to CE-CABG graft failure. Dual antiplatelet therapy (DAT) and warfarin plus aspirin (WPA) are the two most common anticoagulation strategies post CE-CABG. This retrospective study compares the clinical outcomes and graft failure rates associated with these two approaches. METHODS: This study is a retrospective cohort study. Between July 2016 and April 2024, 102 patients with diffuse CAD underwent CE-CABG. Six patients were excluded. In total, 96 patients (mean age 59.8 ± 7.7 years) enrolled in the study (43 in DAT group and 53 in WPA group). The DAT group received aspirin (100 mg, qd) and clopidogrel (75 mg, qd) for 1 year postoperatively, transitioning to aspirin (100 mg, qd) after 1 year. The WPA group received warfarin (international normalized ratio, INR remained at 1.8-2.5) and aspirin (100 mg, qd) for 3 months postoperatively, followed by DAT after 3 months, changed to aspirin monotherapy after 1 year. The primary endpoint was graft failure of the CE-CABG graft. RESULTS: Four patients died during the perioperative period (1 in DAT group, 3 in WPA group), resulting in an overall perioperative mortality rate of 4.2%. Five patients were lost for follow-up. Mean follow-up time was 38 months. Three patients died during the follow-up period (1 in DAT group, 2 in WPA group). The CE-CABG graft patency of the WPA group was significantly higher compared to the DAT group (88.1% vs. 50.0%, P < 0.001). Kaplan-Meier analysis showed that the median graft failure time was significantly longer in the WPA group (77 months, 95% CI 69-85) compared to the DAT group (73 months, 95% CI 17-129, P = 0.017). A higher proportion of the DAT group was classified as NYHA III-IV compared to the WPA group (26.2% vs. 10.2%, P = 0.046). One patient of the WPA group had a gastrointestinal bleeding event, and the overall incidence of bleeding events was not statistically different between the two groups. CONCLUSION: Using the WPA strategy after CE-CABG significantly reduces the rate of graft failure and improves cardiac function without increasing the risk of bleeding events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinPlatelet Aggregation InhibitorsCoronary Artery BypassCoronary Artery DiseaseAnticoagulantsAspirinEndarterectomyDual Anti-Platelet TherapyHumansRetrospective StudiesMaleMiddle AgedFemaleAgedTime FactorsRisk FactorsTreatment OutcomeClopidogrel

Stichwörter der Autor:innen

Anticoagulation strategyCoronary artery diseaseCoronary endarterectomyWarfarin

Substanzen

WarfarinPlatelet Aggregation InhibitorsAnticoagulantsAspirinClopidogrel

Autor:innen und Institutionen

  • Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, The Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangzhou, Guangdong Province, China.
  • The Department of Cardiovascular Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
  • Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, The Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangzhou, Guangdong Province, China. suntucheng@126.com.
  • Cardiac Surgery Unit, Guangdong Provincial People's Hospital, No.106, Zhongshan 2nd Road, Guangzhou, Guangdong Province, China. suntucheng@126.com.

ORCID-Profile: Jianfan Zhen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhen, J., Luo, X., Liu, J., Chen, Z., Wu, J., & Sun, T. (2026). Impact of Warfarin and Dual Antiplatelet Therapy on Graft Failure After Coronary Endarterectomy: A Retrospective Cohort Study. Cardiovascular Drugs and Therapy, 40(1), 181-189. https://doi.org/10.1007/s10557-024-07667-w

Vancouver

Zhen J, Luo X, Liu J, Chen Z, Wu J, Sun T. Impact of Warfarin and Dual Antiplatelet Therapy on Graft Failure After Coronary Endarterectomy: A Retrospective Cohort Study. Cardiovascular Drugs and Therapy. 2026;40(1):181-189. doi:10.1007/s10557-024-07667-w

BibTeX
@article{Zhen2026,
  author = {Zhen, Jianfan and Luo, Xiang and Liu, Jie and Chen, Zerui and Wu, Jinlin and Sun, Tucheng},
  title = {Impact of Warfarin and Dual Antiplatelet Therapy on Graft Failure After Coronary Endarterectomy: A Retrospective Cohort Study},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  volume = {40},
  number = {1},
  pages = {181--189},
  doi = {10.1007/s10557-024-07667-w}
}
Kostenlos starten →